Bridging science and patients through strategic collaboration
To accelerate the translation of scientific discoveries into better cancer care, Oncode Institute has formed a strategic alliance with the Oncode Accelerator Foundation, coordinating part of the Oncode Accelerator programme.
This alliance unites academic researchers, clinicians, entrepreneurs, and investors around one shared goal: to bring innovative therapies to patients faster and more efficiently.
Oncode Accelerator: Innovating and accelerating the development of new cancer therapies to address unmet medical needs
Oncode Accelerator is helping to make the development of new cancer therapies faster and more effective. The programme brings together expertise, technology and infrastructure to improve preclinical drug development in the Netherlands and help promising discoveries move towards the clinic.
Three innovation platforms form the foundation of this approach: well-defined Patient Cohorts, patient-derived Organoid models and Artificial Intelligence. Their expertise is brought into early drug development, putting patients more firmly at the centre of how new therapies are developed and tested.
Researchers and drug developers from academia and industry can access funding, scientific expertise and specialised infrastructure through Oncode Accelerator, helping them advance promising research towards new clinical candidates.
Oncode Accelerator is a public-private partnership funded by the Dutch National Growth Fund (NGF) and private partners. The programme is coordinated by Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht and the Oncode Accelerator Foundation.
Oncode Institute’s Role
As one of the initiators of Oncode Accelerator, Oncode Institute brings its valorisation expertise to the programme, helping identify promising research, support researchers and move scientific discoveries closer to clinical development.
This collaboration allows us to:
- Shorten the time from discovery to application
- De-risk early-stage oncology innovations
- Build public-private partnerships with lasting impact
- Strengthen the Netherlands' position as a global leader in cancer innovation
Together, we aim to shorten the path from scientific discovery to new treatments, helping promising research reach people with cancer sooner.
